FDA Clears Subcutaneous Anifrolumab Autoinjector for Moderate to Severe SLE

Why It Matters

A home‑based option could broaden access, lower infusion‑center costs, and improve adherence for SLE patients who struggle with monthly IV visits. The move also strengthens AstraZeneca’s position in the growing biologics market for autoimmune diseases.

Key Takeaways

• SC anifrolumab enables weekly at‑home dosing for SLE patients
• TULIP‑SC showed 29% DORIS remission, 40% low disease activity
• Safety mirrors IV version; serious infections remain primary risk
• No data yet for lupus nephritis or CNS involvement
• Potential to boost adherence and reduce infusion center burden

Pulse Analysis

The introduction of a subcutaneous autoinjector for anifrolumab marks a shift toward patient‑centric delivery in systemic lupus erythematosus therapy. By moving the drug from infusion suites to the home setting, clinicians can address logistical barriers that often delay treatment initiation and maintenance. Weekly self‑administration aligns with broader trends in autoimmune care, where convenience and reduced clinic visits are increasingly valued by both patients and payers.

Efficacy data from the TULIP‑SC phase 3 trial underpin the FDA decision. In a cohort of 367 adults, weekly 120 mg SC dosing produced a statistically significant improvement in the BICLA score at week 52, with 29% of participants achieving DORIS remission and 40% reaching a low disease activity state. Safety signals mirrored those observed with the intravenous formulation—primarily respiratory infections, herpes zoster, and hypersensitivity reactions—reinforcing the drug’s risk profile while offering a comparable therapeutic benefit.

From a market perspective, the autoinjector expands AstraZeneca’s biologics portfolio and may accelerate uptake in a competitive landscape that includes belimumab biosimilars and emerging interferon‑targeted agents. The convenience factor could translate into higher adherence rates, potentially improving real‑world outcomes and justifying premium pricing. Ongoing studies in cutaneous lupus, systemic sclerosis, and lupus nephritis suggest a broader interferon‑blocking strategy, positioning anifrolumab as a versatile platform for future indications.